Skip to content
← Back to this collection

PUBLICATIONS · 23973186

Effect of abiraterone acetate treatment on the quality of life of patients with metastatic castration-resistant prostate cancer after failure of docetaxel chemotherapy.

Open original source → · Download preserved record

Bibliographic metadata only. No full-text article or abstract is reproduced. Absence of a captured notice is not confirmation that a publication is clear of corrections or retractions.

Journal
Eur J Cancer
Publication date
2013 Nov
First author
Harland S

Publication notices

absence is not clearance
true
has correction metadata
false
has expression of concern metadata
false
has retraction in link
false
pubmed marks article retracted
false
pubmed marks retraction notice
false
relationships

    Authors and identifiers

    1. name
      Harland S
      type
      Author
    2. name
      Staffurth J
      type
      Author
    3. name
      Molina A
      type
      Author
    4. name
      Hao Y
      type
      Author
    5. name
      Gagnon DD
      type
      Author
    6. name
      Sternberg CN
      type
      Author
    7. name
      Cella D
      type
      Author
    8. name
      Fizazi K
      type
      Author
    9. name
      Logothetis CJ
      type
      Author
    10. name
      Kheoh T
      type
      Author
    11. name
      Haqq CM
      type
      Author
    12. name
      de Bono JS
      type
      Author
    Complete bibliographic record and source provenance
    authors
    1. name
      Harland S
      type
      Author
    2. name
      Staffurth J
      type
      Author
    3. name
      Molina A
      type
      Author
    4. name
      Hao Y
      type
      Author
    5. name
      Gagnon DD
      type
      Author
    6. name
      Sternberg CN
      type
      Author
    7. name
      Cella D
      type
      Author
    8. name
      Fizazi K
      type
      Author
    9. name
      Logothetis CJ
      type
      Author
    10. name
      Kheoh T
      type
      Author
    11. name
      Haqq CM
      type
      Author
    12. name
      de Bono JS
      type
      Author
    bibliography ids
    1. nci-bib-0a14ddc18951ffcaff308ed8
    book metadata
    content sha256
    efe8235526cf446679d0577b27841534071c3150085d06a6f90a9bde6cc1ff06
    document type
    citation
    dois
    1. 10.1016/j.ejca.2013.07.144
    electronic publication date
    display
    2013 Aug 22
    precision
    day
    year
    2013
    evidence scope
    bibliographic_metadata_only
    id
    pubmed:23973186
    immutable id
    pubmed:23973186@efe8235526cf446679d0577b27841534071c3150085d06a6f90a9bde6cc1ff06
    journal
    abbreviation
    Eur J Cancer
    issn electronic
    1879-0852
    issn print
    0959-8049
    issue
    17
    name
    European journal of cancer (Oxford, England : 1990)
    nlm unique id
    9005373
    pages
    3648-57
    volume
    49
    languages
    1. eng
    notices
    absence is not clearance
    true
    has correction metadata
    false
    has expression of concern metadata
    false
    has retraction in link
    false
    pubmed marks article retracted
    false
    pubmed marks retraction notice
    false
    relationships
      outcomes validated
      false
      pmid
      23973186
      provenance
      batch id
      0a08f044391426feb8ef
      provider
      NCBI PubMed ESummary
      record sha256
      d73153bcfc25cfeb43a5a6b4b25ba1b0ca30939fa518af0973bcfc27de553ab4
      response sha256
      d94e6242343e5962374663e5e5f0191e7b595329228d2e360db95a280e588409
      retrieved at
      2026-09-09T23:46:57.614689+00:00
      publication date
      display
      2013 Nov
      precision
      month
      year
      2013
      publication types
      1. Clinical Trial, Phase III
      2. Journal Article
      3. Randomized Controlled Trial
      4. Research Support, Non-U.S. Gov't
      record status
      PubMed - indexed for MEDLINE
      schema version
      1.0
      source url
      https://pubmed.ncbi.nlm.nih.gov/23973186/
      title
      Effect of abiraterone acetate treatment on the quality of life of patients with metastatic castration-resistant prostate cancer after failure of docetaxel chemotherapy.

      Preserved source evidence · Not medical advice